Recent findings reported by Turek et al. proved brown tumour to be one of the many pathologies with an activating KRAS-mutation, prompting the hypothesis that it is a true, mutation-driven neoplasm that requires a ‘second hit’ (i.e., hyperparathyroidism) to arise [18]. The gene discussed is KRAS; the disease is hyperparathyroidism.